focus -WSS

focus

author：fashion 2025-10-01 03:41:03 - browse：39131

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Britney Spears to release memoir, 'The Woman In Me,' later this year

WSS

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

After half a century, Israel moves to evict squatter from his cave home on the beach

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Iowa House, Senate pass 6

New research casts further doubt on a common procedure used with IVF

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

knowledge

focus

focus

Jerome Adams on the need for new antivirals for Covid

Britney Spears to release memoir, 'The Woman In Me,' later this year

Virginia high school admissions case could be legal follow

Lecanemab for Alzheimer's is coming. Is the health system ready?

Duchenne breakthrough therapy leaves behind pioneering families

Grail's uphill battle for Medicare to cover its cancer screening test

As demand for Covid shots wanes, Moderna seeks its next success

Charles Manson follower Leslie Van Houten released from prison after 53 years

Walensky prepares to leave CDC — and Congress — behind

New research casts further doubt on a common procedure used with IVF

hotspot

Why ADHD is under

Cuban government calls US nuclear submarine stop a 'provocative escalation'

France's anti

One Duchenne patient's bittersweet hope for new treatment

How are insurers handling Leqembi and related scans?

Palantir health business leans on meeting customers’ needs

hotspot

focus

explore

entertainment